Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266299 · ClinicalTrials.gov registry record · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Kyowa Kirin Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
- 11
- Study locations
NCT06266299: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Kyowa Kirin Co..
NCT06266299 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that is actively recruiting participants, run by Kyowa Kirin Co.. The registered enrollment target is 101 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06266299, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by Kyowa Kirin Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269. In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies. In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG KK2269
Study Locations (11)
California
- City Of Hope National Medical Center - Duarte
- Hoag Memorial Hospital Presbyterian - Newport Beach
Tokyo
- National Cancer Center Hospital - Chuo-ku
- Cancer Institute Hospital of JFCR - Koto-Ku
Arizona
- Mayo Clinic Arizona - Scottsdale
Florida
- Mayo Clinic Jacksonville - Jacksonville
Missouri
- Washington University - St Louis
Texas
- The University of Texas Southwestern Medical Center - Dallas
Washington
- University of Washington - Seattle
Aichi-ken
- Aichi Cancer Center - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT06266299 shows while recruiting
NCT06266299 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower).
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT06266299 lists 11 locations in 9 states (California, Tokyo, Arizona).
Frequently Asked Questions
What is clinical trial NCT06266299 about?
NCT06266299 is a clinical study titled "A Study of KK2269 in Adult Participants With Solid Tumors". This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objec...
What is the current status of trial NCT06266299?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2024-01-18. Estimated completion is 2029-03.
What conditions does trial NCT06266299 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT06266299?
The interventions under investigation include: Docetaxel (DRUG), KK2269 (DRUG).
Who is sponsoring clinical trial NCT06266299?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06266299 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06266299's enrollment target sits among peer trials
101 232nd of 454 higher than 223 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06942949 · 101 participants · NA
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI